Viral Safety: The AFSSAPS Speaks Out About the Regulatory Environment

Add bookmark

Pharma IQ

Contaminations in biological products in 2009 and the porcine circovirus contamination of GSK’s Rotarix vaccine in March of this year has highlighted the issue of viral safety in biologics more than ever before. Marc Martin, Viral Safety Assessor at AFSSAPS, joins Helen Winsor from Pharma IQ, to discuss the evolution of the requirements for viral clearance. In this interview, he gives a general overview of the regulatory environment and talks about where we are up to in the move...
To continue reading this story get free access